Loading company…
Orionis Biosciences develops small-molecule therapies and molecular design technologies.
Orionis Biosciences uses its Allo-Glue™ platform to discover small-molecule molecular glues and its A-Kine™ technology to develop treatments intended to trigger anti-tumor immune responses. Founded in 2015, the company is based in Waltham, Massachusetts, US, and is led by CEO Nikolai Kley. In October 2022, it raised USD 55 million from Cormorant Asset Management and returning investor Novartis to advance research and cancer immunotherapy programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in